共 110 条
[1]
Care D(2022)9 Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes Diabetes Care 45 S125-S143
[2]
Suppl SS(2019)Estimation of globalinsulin use for type 2 diabetes, 2018–30: a microsimulation analysis Lancet Diabetes Endocrinol 7 25-33
[3]
Basu S(2018)Management of hyperglycaemia in type 2 diabetes a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD) Diabetologia 61 2461-2498
[4]
Yudkin JS(2020)Erratum: 2019 updateto: Management of hyperglycemia in type 2 diabetes, 2018 A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD) Diabetes Care 43 487-493
[5]
Kehlenbrink S(2014)Glucagon-likepeptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes Diabetes Care 37 2763-2773
[6]
Davies JI(2014)Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis Lancet 384 2228-2234
[7]
Wild SH(2017)Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic reviewand meta-analysis of randomized controlled trials Diabetes Care 40 614-624
[8]
Lipska KJ(2016)Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial Diabetes Care 39 1972-1980
[9]
Davies MJ(2016)Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levelsin patients with uncontrolled type 2 diabetes: the DUAL v randomized clinical trial JAMA J Am Med Assoc 315 898-907
[10]
D'Alessio DA(2019)GLP-1 receptor agonist added toinsulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review andmeta-analysis Diabetes Metab Res Rev 35 e3082-2518